Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of transthyretin amyloidosis cases
3.2.1.2 Development of novel therapies
3.2.1.3 Rising geriatric population
3.2.1.4 Advancements in diagnostics techniques
3.2.2 Industry pitfalls & challenges
3.2.2.1 Limited treatment options
3.2.2.2 High cost of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 ATTR amyloidosis with polyneuropathy (ATTR-PN)
5.3 ATTR amyloidosis with cardiomyopathy (ATTR-CM)
Chapter 6 Market Estimates and Forecast, By Disease Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Hereditary transthyretin amyloidosis
6.2.1 Polyneuropathy
6.2.2 Cardiomyopathy
6.2.3 Mixed type
6.3 Wild type transthyretin amyloidosis
Chapter 7 Market Estimates and Forecast, By Drug type, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Tafamidis
7.3 Patisiran
7.4 Inotersen
7.5 Other drug types
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Parenteral
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail drug stores
9.4 Online pharmacy
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends, by region
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Acrotech Biopharma, LLC
11.2 Alnylam Pharmaceuticals, Inc.
11.3 AstraZeneca PLC
11.4 Astellas Pharma Inc.
11.5 BridgeBio Pharma, Inc.
11.6 Bristol-Myers Squibb Company
11.7 Ionis Pharmaceuticals, Inc.
11.8 Johnson & Johnson
11.9 Prothena Biosciences Limited
11.10 Pfizer Inc.
11.11 SOM Innovation Biotech, S.L.
